Use of a sirna for treating cancer
AssigneeSelexel, Inc.
InventorsFlorence CABON, Hilary BROOKS, Maud CHUSSEAU, Stéphanie DELMAS
Life of this patent
Estimating the term…
Abstract
Disclosed is a composition including at least one siRNA, the siRNA hybridising with a coding or non-coding mNRA, in which it induces degradation or inhibits translation, the expression of the mRNA or of the protein for which it codes being implicated in a pathology, for the use of same in the prevention and/or the treatment of the pathology, the composition being formulated for a continuous systemic administration mode, and a device including such an administration mode.
Claims18
1-17. (canceled)
A Method for the prevention and/or treatment of a pathology comprising the administration of a composition comprising at least one siRNA, said siRNA hybridizing with a mRNA, coding or non-coding, of which it induces the degradation or of which it inhibits the translation, the expression of said mRNA or of the protein for which it encodes being involved in said pathology, said composition being formulated for a continuous systemic mode of administration.
A device providing a means of continuous systemic mode of administration of a composition comprising at least one siRNA, said siRNA hybridizing with a mRNA, coding or non-coding, of which it induces the degradation or of which it inhibits the translation, the expression of said mRNA or of the protein for which it encodes being involved in said pathology, said composition being formulated for a continuous systemic mode of administration, said means of continuous systemic mode of administration being in particular an osmotic pump, a pump-syringe, an elastomeric pump, a peristaltic pump, an “intelligent” pump, a “patch” pump, or a polymeric matrix or a hydrogel, or any other biodegradable compound for slowly and continuously releasing the siRNA so that it is systemically distributed in the body.
Dependencies are inferred from the claim text.